EMBLAVEOTM is the first and only monobactam/?-lactamase inhibitor combination antibiotic therapy approved by the USFDA
Cancer cases in India estimated to reach 1.57 million in 2025
This innovative formulation combines cutting-edge ingredients is a first of its kind in India to have a Duo-Lipo technology
It will bring together renowned global experts in the field to discuss groundbreaking advances in biomaterials and their clinical applications
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
EBITDA rose to Rs. 14.8 crore, marking a 16.5% y-o-y increase, while net profit surged to Rs. 6.4 crore
AA Signature provides an innovative approach to treatment planning that focuses on patient outcomes
These solutions combine scientifically or clinically validated, regulatory-approved probiotic strains with precise dosing
The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Subscribe To Our Newsletter & Stay Updated